Shanghai RAAS Blood Products Co., Ltd.
Clinical trials sponsored by Shanghai RAAS Blood Products Co., Ltd., explained in plain language.
A Chinese blood products company manufacturing plasma-derived therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New shot aims to cut bleeding in hemophilia patients Results expected Dec 2026 (estimated)
- New injection aims to curb bleeding in rare clotting disorder Results expected Feb 2027 (estimated)